NCT01950520 - Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2014

Primary Completion Date

December 17, 2022

Study Completion Date

June 11, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

Propranolol

Propanolol 160mg, oral, by mouth (Cohort 1 only)

DRUG

Pindolol

Pindolol 20mg, oral, by mouth (Cohort 1 only)

DRUG

Dantrolene

Dantrolene 100mg, oral, by mouth (Cohort 1 only)

DRUG

Magnesium Sulfate

Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)

DRUG

Caffeine

Caffeine 200mg, oral, by mouth (Cohort 2 only)

DRUG

Qsymia

Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)

DRUG

Topiramate

Topiramate 200mg, oral, by mouth (Cohort 2 only)

BEHAVIORAL

Phentermine

Phentermine 37.5mg, oral, by mouth (Cohort 2 only)

DRUG

Naltrexone

Naltrexone 100mg, oral, by mouth (Cohort 2 only)

DRUG

Mirabegron 50mg

Mirabegron 50mg, oral, by mouth (Cohort 3 only)

DRUG

Mirabegron 200mg

Mirabegron 200mg, oral, by mouth (Cohort 3 only)

DRUG

Placebo Cohort 1

Placebo, oral, by mouth (Cohort 1 only)

DRUG

Placebo Cohort 2

Placebo, oral, by mouth (Cohort 2 only)

DRUG

Placebo for Mirabegron

Placebo for Mirabegron, oral, by mouth (Cohort 3 only)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH